Quality prescribing for Benzodiazepines and z-drugs: guide for improvement 2024 to 2027

References

1. Information Services Division. Medicines used in mental health: Years 2009/10 to 2018/19. 2019. URL: https://webarchive.nrscotland.gov.uk/20200214122006/https://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/2019-10-22/2019-10-22-PrescribingMentalHealth-Report.pdf?14530581236 (Accessed 3 June 2024)

2. King D.J., Griffiths K, Reilly P.M., et al. Psychotropic drug use in Northern Ireland 1966-80: prescribing trends, inter- and intra-regional comparisons and relationship to demographic and socioeconomic variables. Psychological Medicine 1982;12(4):819-33.

3. Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance: Realistic prescribing. 3rd ed. Edinburgh: Scottish Government; 2018. URL: https://www.therapeutics.scot.nhs.uk/polypharmacy/ (Accessed 2 February 2024)

4. Health Improvement Scotland, 2022. Why ask what matters? What matters to you? URL: https://www.whatmatterstoyou.scot/ (Accessed 29 November 2023)

5. Taylor S, Annand F, Burkinshaw P, et al. Dependence and withdrawal associated with some prescribed medicines: An evidence review. 2019. URL: https://assets.publishing.service.gov.uk/media/5fc658398fa8f5474c800149/PHE_PMR_report_Dec2020.pdf (Accessed 3 June 2024)

6. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142.

7. Johnson C.F., Ali Nassr O, Harpur C, Kenicer D, Thom A, Akram G. Benzodiazepine and Z-drug prescribing from acute psychiatric inpatient discharge to long-term care in the community. Pharmacy Practice. 2018;16(3):1256.

8. Johnson C.F., Liddell K, Guerri C, Findlay P, Thom A. Medicines reconciliation at the community mental health team-general practice interface: Quality improvement study. BJPsych Bull. 2020;44(1):12-18.

9. NHSGGC PostScript Primary Care. Reducing prescribing of hypnotics and anxiolytics. URL: http://www.ggcprescribing.org.uk/media/uploads/ps_primary_care/pspc_may_2014.pdf. Updated May 2014. (Accessed 11 June 2024)

10. National Institute for Health and Care Excellence. NICE NG217: Epilepsies in children, young people and adults, 2022. URL: https://www.nice.org.uk/guidance/ng217/ (Accessed 11 June 2024)

11. Johnson C, F., Frei C, Downes N, McTaggart S, A., Akram G. Benzodiazepine and Z-hypnotic prescribing for older people in primary care: A cross-sectional population-based study. Br J Gen Pract. 2016;66(647):e410-e415.

12. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry: The Journal of the Association of European Psychiatrists. 2013;28(1):7-20.

13. Joint Formulary Committee. British national formulary, Hypnotics and anxiolytics. London: BMJ Group and Pharmaceutical Press; 2020. URL: https://bnf.nice.org.uk/treatment-summaries/hypnotics-and-anxiolytics/. (Accessed 3 June 2024)

14. Baldwin D.S., Anderson I.M., Nutt D.J., et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British association for psychopharmacology. Journal of Psychopharmacology. 2014;28(5):403-439.

15. National Institute for Health and Care Excellence. NICE CG113. Generalised anxiety disorder and panic disorder in adults: Management ed; 2019, (updated June 2020). www.nice.org.uk/guidance/cg113. (Accessed 24 November 2023)

16. Olson L.G., Hypnotic hazards: Adverse effects of zolpidem and other z-drugs. Australian Prescriber. 2008;31(6):146-149.

17. Weich S, Pearce H.L., Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: Retrospective cohort study. BMJ. 2014;348:g1996.

18. Tiihonen J., MittendorferRutz E., Torniainen M., Alexanderson K., Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. Am J Psychiatry. 2016;173(6):600-606.

19. Johnson Chris F, Barnsdale Lee R, McAuley A. Investigating the role of benzodiazepines in drug-related mortality – A systematic review undertaken on behalf of the Scottish National Forum on drug-related deaths. 2016. URL: https://www.scotpho.org.uk/resources/scotpho-reports-and-papers/investigating-the-role-of-benzodiazepines-in-drug-related-mortality-a-systematic-review-undertaken-on-behalf-of-the-scottish-national-forum-on-drug-related-deaths/ (Accessed 3 June 2024)

20. Ashton H. Toxicity and adverse consequences of benzodiazepine use. Psychiatric Annals. 1995;25(3):158-165.

21. Kripke D.F.. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007;7:42.

22. Otto M.W., Bruce S.E., Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: Issues in the treatment of a patient in need. J Clin Psychiatry. 2005;66(Suppl 2):34-38.

23. National Institute for Health and Care Excellence 2022. Clinical Knowledge Summary. Scenario: Management – Back pain – low (without radiculopathy). https://cks.nice.org.uk/topics/back-pain-low-without-radiculopathy/management/management/ (Accessed 24 November 2023)

24. National Institute for Health and Care Excellence. NICE NG59. low back pain and sciatica in over 16s: Assessment and management (update 2020). 2016. URL: https://www.nice.org.uk/guidance/ng59 (Accessed 29 November 2023)

25. Scottish Palliative Care Guidelines. Midazolam in Palliative Care. 2024. URL: https://www.palliativecareguidelines.scot.nhs.uk/guidelines/medicine-information-sheets/midazolam-in-palliative-care.aspx (Accessed 3 June 2024)

26. National Institute for Health and Care Excellence 2021. Clinical Knowledge Summary. Palliative cancer care - pain: Scenario: Managing muscle spasm pain. URL: https://cks.nice.org.uk/topics/palliative-cancer-care-pain/management/managing-muscle-spasm-pain/ (Accessed 24 November 2023)

27. Gunja N. In the zzz zone: The effects of Z-drugs on human performance and driving. Journal of Medical Toxicology. 2013;9(2):163-171.

28. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: A systematic review and meta-analysis of epidemiological and experimental evidence. Drug Safety. 2011;34(2):125-156.

29. Drugs and driving: the law - GOV.UK. URL: https://www.gov.uk/drug-driving-law. (Accessed 24 November 2023)

30. National Records of Scotland. Drug-related deaths in Scotland in 2019. 2020. URL: https://webarchive.nrscotland.gov.uk/20210316220211/https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2019 (Accessed 3 June 2024)

31. Stewart I, Tough A. The examination of illicit blue diazepam tablets. 2014; Report.

32. Svensson S.A., Hedenrud T.M., Wallerstedt S.M., Attitudes and behaviour towards psychotropic drug prescribing in Swedish primary care: A questionnaire study. BMC family practice. 2019;20(1):4.

33. Bowers H.M., Williams S.J., Geraghty A.W.A., et al. Helping people discontinue long-term antidepressants: Views of health professionals in UK primary care. BMJ Open. 2019;9(7):e027837.

34. Johnson C, Thomson A. Prescribing support pharmacists support appropriate benzodiazepine and Z-drug reduction 2008/09 – experiences from north Glasgow. Clin Pharm. 2010;3(Supp 1):S5-S6.

35. Hughes L.M., Holden J.D., Tree A.M., Audit as a method of reducing benzodiazepine prescribing in general practice. J Clin Eff. 1997;2(3):79-82.

36. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: A systematic review and meta-analysis. British Journal of General Practice. 2011;61(590):e573-8.

37. Towle I, Adams J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in paisley. Pharmaceutical Journal. 2006;276(7386):136-138.

38. Midlov P., Bondesson A., Eriksson T., Nerbrand C., Hoglund P. Effects of educational outreach visits on prescribing of benzodiazepines and antipsychotic drugs to elderly patients in primary health care in southern Sweden. Fam Pract. 2006;23(6):60-64.

39. Department of Health and Social Care, Good for you, good for us, good for everybody, 2021, URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1019475/good-for-you-good-for-us-good-for-everybody.pdf (Accessed: 24 November 2023).

40. Royal Pharmaceutical Society, Sustainability Policy, 2021, URL: https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacys-role-in-climate-action-and-sustainable-healthcare (Accessed: 24 November 2023).

41. Royal College of General Practitioners Council Motion, Sustainable development, climate change and green issues, 2019, URL: https://www.rcgp.org.uk/policy/rcgp-policy-areas/climate-change-sustainable-development-and-health (Accessed: 24 November 2023).

42. Scottish Environment Protection Agency (SEPA). Pharmaceuticals in wastewater. URL: https://informatics.sepa.org.uk/EnvironmentalPharmaceuticals/ (Accessed 24 November 2023)

43. Sustainable Markets Initiative Health Systems Task Force, in collaboration with BCG, Decarbonising Patient Care Pathways, November 2022. URL: smi-hstf-pcp-whitepaper.pdf (storyblok.com) (Accessed 24 June 2024)

44. Lebreton M, Malgouyres J.M., Carayon J.L., Bonnafé E, Géret F. Effects of the anxiolytic benzodiazepine oxazepam on freshwater gastropod reproduction: a prospective study. Ecotoxicology. 2021 Nov;30(9):1880-1892. doi: 10.1007/s10646-021-02453-y. Epub 2021 Aug 11. PMID: 34379245.

45. T. Brodin et al., Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations.Science339,814-815(2013).DOI:10.1126/science.1226850

46. D. Cerveny, T. Brodin, P. Cisar, E.S., McCallum, J. Fick, Bioconcentration and behavioral effects of four benzodiazepines and their environmentally relevant mixture in wild fish, Science of The Total Environment, Volume 702, 2020, 134780, ISSN 0048-9697. doi.org/10.1016/j.scitotenv.2019.134780.

47. Fabiana Kalichak, Renan Idalencio, João Gabriel S. Rosa, Thiago A. de Oliveira, Gessi Koakoski, Darlan Gusso, Murilo S. de Abreu, Ana Cristina V. Giacomini, Heloísa H.A. Barcellos, Michele Fagundes, Angelo L. Piato, Leonardo J.G. Barcellos, Waterborne psychoactive drugs impair the initial development of Zebrafish, Environmental Toxicology and Pharmacology, Volume 41, 2016, Pages 89-94, ISSN 1382-6689, URL: https://doi.org/10.1016/j.etap.2015.11.014. (Accessed 24 November 2023)

48. Claudia Rivetti, Bruno Campos, Carlos Barata, Low environmental levels of neuro-active pharmaceuticals alter phototactic behaviour and reproduction in Daphnia magna, Aquatic Toxicology, Volume 170, 2016, Pages 289-296, ISSN 0166-445X, URL: https://doi.org/10.1016/j.aquatox.2015.07.019. (Accessed 24 November 2023)

49. Alistair B.A. Boxall, Paul Johnson, Edward J. Smith, Chris J. Sinclair, Edward Stutt, and Len S. Levy. Uptake of Veterinary Medicines from Soils into Plants. Journal of Agricultural and Food Chemistry 2006 54 (6), 2288-2297 DOI: 10.1021/jf053041t

50. Nassiri Koopaei N, Abdollahi M. Health risks associated with the pharmaceuticals in wastewater. Daru. 2017 Apr 12;25(1):9. doi: 10.1186/s40199-017-0176-y. PMID: 28403898; PMCID: PMC5389172.

51. Chubin Zhang, Leon Barron, Stephen Sturzenbaum, The transportation, transformation and (bio)accumulation of pharmaceuticals in the terrestrial ecosystem, Science of The Total Environment, Volume 781, 2021, 146684, ISSN 0048-9697, URL: https://doi.org/10.1016/j.scitotenv.2021.146684. (Accessed 29 November 2023)

52. Cooney G.M., Dwan K, Greig C.A., et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2013(9):CD004366.

53. McGrath M, Duncan F, Dotsikas K, et al. Effectiveness of community interventions for protecting and promoting the mental health of working-age adults experiencing financial uncertainty: A systematic review. J Epidemiology Community Health. 2021;75:665-673.

54. Coventry P.A., Brown J.E., Pervin J., et al. Nature-based outdoor activities for mental and physical health: Systematic review and meta-analysis. SSM - Population Health. 2021;16(pagination): Arte Number: 100934. Date of Publication: December 2021.

55. Simon, L., Steinmetz, L., Feige, B., Benz, F., Spiegelhalder, K. and Baumeister, H., 2023. Comparative efficacy of onsite, digital, and other settings for cognitive behavioral therapy for insomnia: a systematic review and network meta-analysis. Scientific Reports, 13(1), p.1929.

56. National Institute for Health & Care Excellence (2024). Clinical Knowledge Summary. Scenario: Managing insomnia URL: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/#good-sleep-hygiene. (Accessed 17 July 2024).

57. Glass J, Lanctot K.L., Herrmann N, Sproule B.A., Busto UE. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.

58. National Institute for Health and Care Excellence. NICE NG116. post-traumatic stress disorder. 2018. URL: https://www.nice.org.uk/guidance/NG116 (Accessed 29 November 2023).

59. National Institute for Health & Care Excellence. NICE NG222: Depression in adults: treatment and management; 2022. URL: https://www.nice.org.uk/guidance/ng222. (Accessed 23 February 2024).

60. Ogawa Y, Takeshima N, Hayasaka Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database of Systematic Reviews. 2019;6:001026.

61. National Institute for Health and Care Excellence. Chronic pain (primary and secondary) in over 16s: Assessment of all chronic pain and management of chronic pain (NG193). 2021. URL: https://www.nice.org.uk/guidance/ng193 (Accessed 3 June 2024)

62. Webster L, Costafreda Gonzalez S, Stringer A, Lineham A, Budgett J, Kyle S, et al. Measuring the prevalence of sleep disturbances in people with dementia living in care homes: a systematic review and meta-analysis. Sleep. 2020;43(4). doi: 10.1093/sleep/zsz251

63. Capezuti, E., Sagha Zadeh, R., Pain, K., Basara, A., Jiang, N.Z. and Krieger, A.C., 2018. A systematic review of non-pharmacological interventions to improve nighttime sleep among residents of long-term care settings. BMC geriatrics, 18, pp.1-18.

64. Wilfling, D. et al. (2021) ‘Characteristics of multicomponent, nonpharmacological interventions to reduce or avoid sleep disturbances in nursing home residents: a systematic review’, International Psychogeriatrics, 33(3), pp. 245–273. doi:10.1017/S1041610

65. Wheeler A., Kairuz T., Sheridan J., McPhee E. Sedative-hypnotic treatment in an acute psychiatric setting: Comparison with best practice guidance. Pharmacy World and Science. 2007;29(6):603-610.

66. Peters S.M., Knauf K.Q., Derbidge C.M., Kimmel R, Vannoy S. Demographic and clinical factors associated with benzodiazepine prescription at discharge from psychiatric inpatient treatment. General Hospital Psychiatry. 2015;37(6):595-600.

67. Tiihonen J, Suokas J.T., Suvisaari J.M., Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-483.

68. Bazire S. Psychotropic drug directory. Lloyd-Reinhold Publications; 2018.

69. Taylor D.M., Barnes TRE, Young A.H., eds. The Maudsley prescribing guidelines in psychiatry. 14th ed. Chichester, UK: Wiley-Blackwell; 2021.

70. Richardson K., Loke Y.K., Fox C., et al. Adverse effects of Z-drugs for sleep disturbance in people living with dementia: A population-based cohort study. BMC Medicine. 2020;18(1) (pagination):Arte Number: 351. Date of Publication: December 2020.

71. Cumming R.G., Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: A review of the evidence. CNS Drugs. 2003;17(11):825-837.

72. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud F.J., Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicology Review. 2006;25(2):79-85.

73. Scottish Drug Deaths Taskforce and Public Health Scotland. Medical assisted treatment (MAT) standards informed response for benzodiazepine harm reduction. URL: https://www.publichealthscotland.scot/publications/mat-standards-informed-response-to-benzodiazepine-harm-reduction-guidance/. Updated 2023. (Accessed 23 January 2024)

74. Donoghue J, Lader M. Antidepressants are associated with increased length of hypnotic use in primary care. European Neuropsychopharmacology. 2008.;18(S4):S326-S327.

75. Johnson C.F., Dougall N.J., Williams B., MacGillivray S.A., Buchanan A.I., Hassett R.D., Patient factors associated with SSRI dose for depression treatment in general practice: A primary care cross sectional study. BMC family practice. 2014;15:210.

76. Furukawa T.A., Cipriani A, Cowen P.J., Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609.

77. Dold M., Bartova L., Rupprecht R., Kasper S. Dose escalation of antidepressants in unipolar depression: A meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom. 2017;86(5):283-291.

78. Johnson C.F., Maxwell M, Williams B, et al. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Medicine 2022;1(1):e000017. doi: 10.1136/bmjmed-2021-000017

79. Paton C., Banham S., Whitmore J. Benzodiazepines in schizophrenia: Is there a trend towards long-term prescribing? Psychiatric Bulletin. 2000;24(3):113-115.

80. Dold M., Li C., Tardy M., Khorsand V., Gillies D., Leucht S. Benzodiazepines for schizophrenia. Cochrane database of systematic reviews (Online). 2012;11:006391.

81. Scottish Government, Effective Prescribing and Therapeutics Branch and Public Health Scotland. National Therapeutic Indicators 2018.

82. Park T.W., Sikov J., dellaBitta V., Saitz R., Walley A.Y., Drainoni M.L., "It could potentially be dangerous. but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. J Subst Abuse Treat. 2021;131(pagination):Arte Number: 108455. Date of Publication: December 2021.

83. General Medical Council. Good practice in prescribing and managing medicines and devices. URL: https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices. Updated 2022. (Accessed 24 November 2023)

84. Ashton H. The Ashton manual. benzodiazepines: How they work and how to withdraw. URL: http://www.benzo.org.uk/. (Accessed 24 November 2023)

85. Ribeiro P.R.S., Schlindwein A.D., Benzodiazepine deprescription strategies in chronic users: A systematic review. Family Practice. 2021(pagination): Date of Publication: 28 April 2021.

86. Independent Expert Working Group Drug Misuse and Dependence. Clinical Guidelines on Drug Misuse and Dependence Update 2017: UK guidelines on clinical management. London: Department of Health, 2017.

87. Lewis G. Equivalent doses of oral benzodiazepines. UKMI Q&A. 2020.

88. Silvercloud, ‘How to assess for client suitability for online CBT programmes’, 2014; https://www.silvercloudhealth.com/hubfs/Collaterals/Ebooks/Ebook_client_suitability.pdf

89. Alzheimer Scotland, ‘Responding to Stress and Distress in Dementia’, 2018. URL: https://www.alzscot.org/sites/default/files/2019-11/Understanding%20stress%20and%20distress%20in%20dementia.pdf (Accessed 3 June 2024).